Trial Rethink: New Medical Journal Paradigm Should Factor Into Study Plans
This article was originally published in The Gray Sheet
Executive Summary
Firms may need to become more selective in deciding which trials to conduct if a barrage of negative results are to be avoided, Robert Klepinski, president of Klepinski and DuVal, advised during a recent Regulatory Affairs Professionals Society meeting in Washington, D.